3 New Strong Buy Ratings from Top-Rated Analysts: 02/24/2026

By Jessie Moore, Stock Researcher and Writer
February 24, 2026 5:00 AM UTC
3 New Strong Buy Ratings from Top-Rated Analysts: 02/24/2026

All of the below stocks have great Zen Ratings — and the backing of Wall Street’s brightest and best.

  • Roku (ROKU) — Streaming giant projected to surge 73% earnings growth
  • AbbVie (ABBV) — Pharma powerhouse rising strong after Humira patent cliff
  • Valmont Industries (VMI) — Infrastructure play riding utility sector to new highs

P.S. Get more alerts like this daily … Try WallStreetZen Premium.


A note from our sponsors...

Buffett's $114 Secret In 1943, a teenage Warren Buffett put $114 into a special type of account called "The 29% Account." Today, that single, $114 investment would be worth over $15 million. Your bank never told you about this. Click Here to See How It Works

1. AbbVie (NYSE: ABBV)

AbbVie has navigated the Humira patent cliff and come out swinging — with a jaw-dropping 96% earnings growth and a next-generation drug portfolio in immunology and oncology that has Wall Street increasingly bullish on what's ahead.

Zen Rating: B (Buy)see full analysis

Recent Price: $224.73 — get current quote

Max 1-year forecast: $299.00

Why we're watching:

  • Analyst support: ABBV commands Wall Street confidence with 9 Strong Buy ratings, 3 Buy ratings, and 3 Hold ratings from 15 covering analysts. See the ratings
  • Piper Sandler researcher David Amsellem (a top 6% rated analyst) recently maintained his Strong Buy rating with a $299 price target (33% potential upside!) noting that AbbVie's strategic acquisitions will enhance its revenue base significantly and emphasizing the company is well-positioned with recent product launches.
  • Guggenheim's Vamil Divan (a top 3% rated analyst) sees significant upside potential as AbbVie continues building its post-Humira growth story.
  • Industry ranking context: ABBV is currently the 4th highest-rated stock in the General Drug Manufacturer industry, which has an Industry Rating of A.
  • Zen Rating highlights: Buy (B) stocks average +19.88%/yr — ABBV actually ranks in the top 12% of the 4600+ stocks we track. 
  • Component Grades: Safety achieves an elite A rating, while Financials scores a B, reflecting the company's strong balance sheet and consistent cash generation capabilities. (See all 7 Zen Component Grades here)

2. Valmont Industries (NYSE: VMI)

Valmont Industries is riding a wave of infrastructure investment straight to its 52-week high — with 31% earnings growth projected and utility sector tailwinds accelerating, this global fabricated metal powerhouse looks primed to keep climbing.

Zen Rating: B (Buy)see full analysis

Recent Price: $471.27 — get current quote

Max 1-year forecast: $510.00

Why we're watching:

  • Analyst support: Unanimous Strong Buy consensus from Wall Street with 2 Strong Buy ratings and 1 Hold rating from 3 covering analysts. See the ratings
  • Stifel Nicolaus researcher Nathan Jones (a top 2% rated analyst) recently maintained his Strong Buy rating with a $501 price target, reflecting confidence in the company's utility-driven growth trajectory.
  • JP Morgan analyst raised their price target to $510 following Q4 and FY 2025 earnings, noting that "utility strength is driving the company's growth" and highlighting accelerating momentum in core infrastructure markets.
  • Industry ranking context: VMI is currently the 1st highest-rated stock in the Conglomerate industry — but be cautious, because it has an Industry Rating of D.
  • Zen Rating highlights: Buy (B) stocks average nearly 20% average annual returns — putting VMI in “above average” territory among the thousands of stocks we track.
  • Component Grades: Financials achieves an outstanding A rating, reflecting strong profit margins of 9.5% and healthy cash flow generation, while Safety earns a B grade indicating solid balance sheet fundamentals. (See all 7 Zen Component Grades here)

3. Roku (NASDAQ: ROKU)

We like ROKU better than Netflix! Roku is capitalizing on the connected TV boom, with earnings growth projected at a staggering 73% and revenue climbing 13% year-over-year — and the numbers suggest this streaming giant is just getting started.

Zen Rating: B (Buy)see full analysis

Recent Price: $88.20 — get current quote

Max 1-year forecast: $150.00

Why we're watching:

  • Analyst support: Strong backing from Wall Street with 10 Strong Buy ratings, 5 Buy ratings, and 2 Hold ratings out of 17 total analysts covering the stock. See the ratings
  • Oppenheimer's Jason Helfstein (a top 2% rated analyst) recently maintained his Buy rating with a $120 price target (over 30% potential upside!) following the company's recent earnings performance.
  • Bank of America raised their price target to $140, suggesting nearly 60% potential upside, attributing the increase to "a raised CY 2027 free cash flow per share estimate and rolling forward BoA's multiple by one year," noting that Roku has considerable room to continue expanding its top and bottom lines.
  • Industry ranking context: ROKU is currently the 2nd highest-rated stock in the Entertainment industry — but beware, because it has an Industry Rating of F.
  • Zen Rating highlights: As a B-rated stock, ROKU is in the 2nd-highest rating tier of stocks we track — a category that has historically beaten the S&P 500’s annual returns.
  • Component Grades: Growth earns top marks with an A rating, while Sentiment also achieves an A, reflecting strong analyst optimism and market momentum despite the challenging industry backdrop. (See all 7 Zen Component Grades here)

What to Do Next?

Want to get in touch? Email us at news@wallstreetzen.com.

WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.